Abstract
Purpose :
To report the efficacy of intravitreal bevacizumab (IVB) injection versus intravitreal triamcinolone acetonide (IVT) for the treatment of persistent non-infectious uveitic cystoid macular edema (CME).
<div class="grammarly-disable-indicator"> </div>
Methods :
Interventional retrospective comparative case series. Thirty-seven consecutive patients (44 eyes) were included. Patients received repeated injections either 1.25 mg of IVB (20 eyes) or 4 mg of IVT (24 eyes). Patients were included if uveitis was completely controlled, and CME was unresponsive to medical treatment in one or both eyes.
<div class="grammarly-disable-indicator"> </div>
Results :
In the IVB group, baseline best-corrected visual acuity (BCVA) was logMAR 1, and improved to 0.8 (p=0.002) at 24 months. In the IVT group, baseline BCVA was logMAR of 1.1 and improved to 0.6 at 24 months (p= 0.001). At 24-month, central macular thickness (CMT) in the IVB group improved from 399.2 µm to 333.7 µm (p< 0.0009) and from 464.4 µm to 316.5 µm (p=0.044) in the IVT group. There was a significant increase in IOP in the IVT group compared with the IVB group at all time points of the study.
<div class="grammarly-disable-indicator"> </div>
Conclusions :
Repeated injections with IVT improve BCVA as effectively as repeated injections with IVB in the long-term management of persistent uveitic CME .
<div class="grammarly-disable-indicator"> </div>
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.